Summary of treatment responses using intravenous lidocaine and greater occipital nerve blocks (GONB) as transitional treatment in short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)
| Intravenous lidocaine | SUNCT (N=35) | SUNA (N=23) | Total (N=58) |
| Mild benefit (<50%) N (%) | 2 (5.7%) | 1 (4.4%) | 3 (5.2%) |
| Good benefit (50%–90%) N (%) | 11 (31.4%) | 6 (26.1%) | 17 (29.3%) |
| Excellent benefit (91%–100%) N (%) | 21 (60.0%) | 14 (60.9%) | 35 (60.3%) |
| Non-responders N (%) | 1 (2.9%) | 2 (8.7%) | 3 (5.2%) |
| Mean duration of benefit in days (±SD) (range) | 21.5±26.4 (3–90) | 23.1±30.8 (4–90) | 22.1±27.3 (3–90) |
| GONB | SUNCT (N=47) | SUNA (N=31) | Total (N=78) |
| Mild benefit (<50%) N (%) | 4 (8.5%) | 4 (12.9%) | 8 (10.3%) |
| Good Benefit (50%–90%) N (%) | 7 (14.9%) | 6 (19.4%) | 13 (16.7%) |
| Excellent benefit (91%–100%) N (%) | 4 (8.5%) | 4 (12.9%) | 8 (10.3%) |
| Non-responders N (%) | 31 (66.0%) | 18 (58.1%) | 49 (62.8%) |
| Mean duration of benefit in days (±SD) (range) | 42.2 (±27.9) (1–90) | 40.3 (±45.3) (7–150) | 41.3 (±36.3) (1–150) |
GONB, greater occipital nerve blockade; N, number.